The HIV vaccine field is increasingly focusing on inducing broadly neutralizing antibodies (bNAbs) that can recognize the virus’s genetic diversity. Recent experimental approaches include germline-targeting vaccines, sequential immunization strategies, mRNA-based immunogens, and nanoparticle platforms displaying engineered HIV envelope (Env) trimers. Several studies published in 2025 and 2026 how these designs guide antibody maturation in humans and generate broad neutralizing responses in nonhuman primates, although no HIV vaccine has yet demonstrated protective efficacy in large clinical trials. Read More
Insilico Medicine Cayman Topco has nominated ISM-9528 as a preclinical candidate for pain management. ISM-9528 targets an undisclosed novel mechanism to offer a brain-penetrant, orally available, non-opioid treatment option for pain. Read More
Mentari Therapeutics Inc. has announced a $200 million private placement to support continued development of its pipeline of targeted biologics for migraine. Read More
Evogene Ltd. and Eleo Inc. have established a strategic scientific collaboration to discover and develop next-generation oral small-molecule inhibitors targeting the PCSK9 pathway for the treatment of hyperlipidemia and cardiovascular diseases. Read More
Shijiazhuang Yiling Pharmaceutical Co. Ltd. has divulged new lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists potentially useful for the treatment of pulmonary fibrosis. Read More
Pancreatic polypeptide (PP) selectively activates NPY4 receptors, a signaling pathway that may become impaired as NPY levels decline during Alzheimer’s disease progression. Researchers from Henan University of Chinese Medicine described P1642-1, a novel PP analogue, in the 5×FAD mouse model of AD. Read More
Outer membrane vesicles (OMVs), naturally released by gram-negative bacteria, are promising platforms for mucosal vaccines due to their immunostimulatory properties and ability to display antigens. Abera Bioscience AB previously developed an OMV platform using genetically engineered bacteria with covalent antigen decoration via Spycatcher/Tag technology. Read More
Work at Chengdu Shibeikang Biological Medicine Technology Co. Ltd. has led to the identification of new gadolinium complexes reported to be potentially useful as magnetic resonance imaging (MRI) contrast agents. Read More
Shanghai Escugen Biotechnology Co. Ltd. has disclosed new antibody-drug conjugates comprising chimeric monoclonal antibodies targeting CD174 (Lewis y) covalently linked to a cytotoxic drug. They are potentially useful for the treatment of cancer. Read More
Abera Bioscience AB has announced, together with clinical partner Radboud University Medical Center, the submission of a clinical trial application in the Netherlands to initiate a phase I trial of its serotype-independent pneumococcal vaccine candidate AB-01.12.
Shenzhen Targetrx Inc. has patented proteolysis targeting chimeras (PROTACs) comprising cereblon ligands coupled to a hepatocyte growth factor receptor (HGFR, MET)-targeting moiety via linker acting as HGFR degradation inducers potentially useful for the treatment of cancer. Read More
Jiangxi Kerui Pharmaceutical Co. Ltd. has reported new sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of acute pain. Read More
Tikva Allocell Pte. Ltd. has closed an $8 million series A financing to support its development of engineered, allogeneic cell therapies for adult and pediatric patients with solid tumors. Read More
